ABIVAX SIGNS AGREEMENT WITH THE FINLAY INSTITUTE

ABIVAX signs agreement with the Finlay Institute to commercialise meningococcal and typhoid vaccines in Asia and Latin America. Under the terms of the agreement, ABIVAX will gain exclusive and non-exclusive distribution rights for three vaccines currently marketed successfully by The Finlay Institute in Cuba :

  • Typhoid: vax‐TyVi – targeting Typhoid
  • Meningococcal: VA‐MENGOC‐BC – targeting Groups B & C Meningococcus
  • Leptospirosis: vax‐SPIRAL – targeting Leptospirosis

Press contacts

Caroline Carmagnol 

abivax@alizerp.com

+ 33 6 64 18 99 59 or
+ 33 1 44 54 36 65

 Standard: +33 1 53 83 08 41